|
Impact of inclisiran on LDL-C over 18 months in patients with ASCVD or risk-equivalent - Results of the Phase 3 ORION-11 trial
|
|
|
Download the PDF  
European Society of Cardiology meeting 2019 Aug 31-Sept 2 Paris
![0909191](../images/090919/090919-3/0909191.gif)
Impact of inclisiran on LDL-C over 18 months in patients with ASCVD or risk-equivalent - Results of the Phase 3 ORION-11 trial  
European Society of Cardiology meeting 2019 Aug 31-Sept 2 Paris
![0909192](../images/090919/090919-3/0909192.gif)
![0909193](../images/090919/090919-3/0909193.gif)
![0909194](../images/090919/090919-3/0909194.gif)
![0909195](../images/090919/090919-3/0909195.gif)
![0909196](../images/090919/090919-3/0909196.gif)
![0909197](../images/090919/090919-3/0909197.gif)
![0909198](../images/090919/090919-3/0909198.gif)
![0909199](../images/090919/090919-3/0909199.gif)
![09091910](../images/090919/090919-3/09091910.gif)
![09091911](../images/090919/090919-3/09091911.gif)
![09091912](../images/090919/090919-3/09091912.gif)
|
|
|
|
|
|
|